COMMUNIQUÉS West-GlobeNewswire

Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients

26/06/2017 - 15:00

DUBLIN - June 26, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a new outcomes-based agreement with Aetna (NYSE:AET) for type 1 and type 2 diabetes patients currently on [...]

Novo Nordisk A/S - Share repurchase programme

26/06/2017 - 13:40

Bagsværd, Denmark, 26 June 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]

Targovax ASA: Registration of capital increase following exercise of employee options and settlement of restricted stock units

26/06/2017 - 09:40

Reference is made to the stock exchange notice of 14 June 2017 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the exercise of employee [...]

Mithra Pharmaceuticals: ESTELLE® PHASE IIB RESULTS ON WELL-BEING AND BODY WEIGHT PUBLISHED IN LEADING PEER-REVIEWED JOURNAL

26/06/2017 - 07:30

PRESS RELEASE Estelle® Phase IIb results on well-being and BODY weight published in LEADING peer-reviewed journal European Journal Of Contraception and Reproductive Health Care publishes article on Phase IIb results of [...]

ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS

26/06/2017 - 07:00

To assess the safety and tolerability of single and multiple doses of caplacizumab in Japanese healthy volunteers To compare the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of caplacizumab in Japanese and [...]

INNATE PHARMA : Results of Annual General Meeting and changes to Innate Pharma's governance and management team

26/06/2017 - 07:00

Results of Annual General Meeting and changes to Innate Pharma's governance and management team · All proposed resolutions were voted according to management's recommendations; · Bpifrance Participations, represented by [...]

INNATE PHARMA : Résultats de l'Assemblée générale et évolutions au sein de la gouvernance et du management de la société

26/06/2017 - 07:00

Résultats de l'Assemblée générale et évolutions au sein de la gouvernance et du management de la société Toutes les résolutions proposées ont fait l'objet d'un vote conforme aux recommandations du Directoire ; Bpifrance [...]

Bone Therapeutics SA: Receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform

26/06/2017 - 07:00

Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform European IP protection for company's allogeneic technology expected until 2029 Gosselies, Belgium, [...]

Bone Therapeutics SA: Reçoit de l'Office Européen des Brevets une notification d'intention de délivrer un brevet pour sa plateforme de thérapie cellulaire osseuse allogénique

26/06/2017 - 07:00

Bone Therapeutics reçoit de l'Office Européen des Brevets une notification d'intention de délivrer un brevet pour sa plateforme de thérapie cellulaire osseuse allogénique Protection de la Propriété Intellectuelle liée à [...]

NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)

23/06/2017 - 18:00

Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved event-free survival in [...]

Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017

23/06/2017 - 17:34

Curetis Reports Results of the Annual Shareholder Meeting Held on June 23, 2017 - Dr. Nils Clausnitzer elected as member of the Supervisory Board Amsterdam, the Netherlands, and Holzgerlingen, Germany, June 23, 2017 -- [...]

Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial

23/06/2017 - 16:45

Bagsværd, Denmark, 23 June 2017 - Novo Nordisk today announced the headline results from a 52-week double-blind phase 2 clinical trial with once-daily subcutaneous semaglutide investigating safety and potential for [...]

SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA

23/06/2017 - 14:00

More than 35 presentations and sessions showcase Shire's gene therapy pipeline and leading factor portfolio Zug, Switzerland - June 23, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), a leading biotechnology company focused [...]

Novo Nordisk A/S: CHMP adopts positive opinion for EU label update of Victoza® based on the LEADER trial

23/06/2017 - 13:40

Bagsværd, Denmark, 23 June 2017 - Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion on update of the EU [...]

uniQure Announces Clinical Data Presentations at the Upcoming International Society on Thrombosis and Hemostasis (ISTH) Congress

23/06/2017 - 13:00

~ Updated, Long-term Results from the Phase I/II Dose-Escalating Study of AMT-060 to be Presented on Monday, July 10, 2017 ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 23, 2017 (GLOBE NEWSWIRE) -- uniQure N.V [...]

Medtronic Announces 7 Percent Increase in Cash Dividend

23/06/2017 - 12:45

40th Consecutive Year of Dividend Increases; Board Authorizes $5 Billion for Share Repurchases DUBLIN - June 23, 2017 - The board of directors of Medtronic plc (NYSE: MDT) today approved a 7 percent increase in its [...]

Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor

23/06/2017 - 10:40

CHMP opinion based on pivotal Phase III trial that showed Kisqali plus letrozole reduced risk of disease progression or death by 44% over letrozole alone among postmenopausal women with HR+/HER2- advanced breast cancer[ [...]

Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®

23/06/2017 - 08:40

New 96-week data support durability and safety of Treatment-free Remission (TFR) in Ph+ CML-CP patients who stop taking Tasigna [1,2] More than 90% of Ph+ CML-CP patients in ENESTfreedom and ENESTop who stopped Tasigna [...]

Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL

23/06/2017 - 08:35

83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data Data evaluating 63 patients demonstrate relapse- [...]